Literature DB >> 6978374

Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses.

E L Morgan, W O Weigle, T E Hugli.   

Abstract

The C3a fragment of the third component of complement was found to have immunosuppressive properties. C3a is capable of suppressing both specific and polyclonal antibody responses. In contrast, C3a had no effect on antigen- or mitogen-induced B or T cell proliferative responses. The carboxy-terminal arginine is essential for C3a to exhibit its immunosuppressive properties. The serum carboxypeptidase inhibitor 2-mercaptomethyl-5-guanodinopentanoic acid, which prevents cleavage of the terminal arginine that would produce C3ades Arg-77, allowed us to assay the effects of C3a on in vitro immune response systems where serum is required. When the terminal arginine is removed from C3a, the resulting C3ades Arg-77 molecule is nonsuppressive. Helper T lymphocytes are the target of C3a-mediated suppression of the immune response. Substitution of T cells by soluble T cell factors was found to abrogate the C3a suppressive activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978374      PMCID: PMC2186691          DOI: 10.1084/jem.155.5.1412

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Lymphokine production by C3b-stimulated B cells.

Authors:  A L Sandberg; S M Wahl; S E Mergenhagen
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

2.  Spontaneous murine B-cell leukaemia.

Authors:  S Slavin; S Strober
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

3.  Bone marrow origin of complement-receptor lymphocytes.

Authors:  P Dukor; C Bianco; V Nussenzweig
Journal:  Eur J Immunol       Date:  1971-12       Impact factor: 5.532

4.  Studies of immunosuppression by cobra venom factor. I. On early IgG and IgM responses to sheep erythrocytes and DNP-protein conjugates.

Authors:  G P Martinelli; T Matsuda; A G Osler
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

5.  Characterization of a spontaneous murine B cell leukemia (BCL1). I. Cell surface expression of IgM, IgD, Ia, and FcR.

Authors:  M R Knapp; P P Jones; S J Black; E S Vitetta; S Slavin; S Strober
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

6.  Purification and partial characterization of human and porcine C3a anaphylatoxin.

Authors:  T E Hugli; E H Vallota; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1975-02-25       Impact factor: 5.157

7.  Plaque Formation in Agar by Single Antibody-Producing Cells.

Authors:  N K Jerne; A A Nordin
Journal:  Science       Date:  1963-04-26       Impact factor: 47.728

8.  In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells.

Authors:  J Misiti; T A Waldmann
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Receptors for complement of leukocytes.

Authors:  W H Lay; V Nussenzweig
Journal:  J Exp Med       Date:  1968-11-01       Impact factor: 14.307

View more
  12 in total

1.  A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.

Authors:  Hua Zhou; Henrik Olsen; Edward So; Emmanuel Mérigeon; Denis Rybin; Jane Owens; Gregory LaRosa; David S Block; Scott E Strome; Xiaoyu Zhang
Journal:  Blood Adv       Date:  2017-03-14

Review 2.  The complement system: 1983.

Authors:  J E Volanakis
Journal:  Surv Immunol Res       Date:  1984

Review 3.  The role of complement in the induction and regulation of immune responses.

Authors:  T G Egwang; A D Befus
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

Review 4.  Regulation of immune response by components of the complement cascade and their activated fragments.

Authors:  W O Weigle; M G Goodman; E L Morgan; T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1983

5.  Potentiation of specific human in vitro immune responses by the Fc portion of human immunoglobulin.

Authors:  E L Morgan; W O Weigle
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

6.  Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment.

Authors:  C Charriaut; A Senik; J P Kolb; M Barel; R Frade
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.

Authors:  R Huey; C M Bloor; M S Kawahara; T E Hugli
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

8.  Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons.

Authors:  Ralf Gutzmer; Margarete Lisewski; Jörg Zwirner; Susanne Mommert; Carola Diesel; Miriam Wittmann; Alexander Kapp; Thomas Werfel
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

9.  Different allotypes of C3 degrade at different rates.

Authors:  P H Kay; S Natsuume-Sakai; J Hayakawa; R L Dawkins
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

10.  Suppression of immune response to Listeria monocytogenes: mechanism(s) of immune complex suppression.

Authors:  H W Virgin; G F Wittenberg; G J Bancroft; E R Unanue
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.